Stifel nearly tripled its price target for GTx (NASDAQ:GTXI) to $45 from $16 after the company reported significant positive new data at the SUFU Winter Meeting for its Phase 2 proof-of-concept study testing, enobosarm, in female patients with stress urinary incontinence (SUI). The stock closed at $16.81 on March 2.Read More
Stifel launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with a “buy” rating and a $32 target price. The stock closed at $19.23 on Jan. 26.Read More
Stifel initiated coverage of GTx (NASDAQ:GTXI) a “buy” rating and $16 price target. The stock closed at $7.51 on Nov. 8.Read More
Stifel raised its price target for “buy-rated” Reata Pharmaceuticals (NASDAQ:RETA) to $50 from $38 after the company reported statistically significant improvements in kidney function from the Phase 2 portion of its Cardinal study evaluating BARD in Alport chronic kidney disease (CKD). The stock closed at $37.66 on July 24.Read More
Stifel upgraded Durect (NASDAQ:DRRX) to “buy” from “hold” and raised its price target to $3 from $1.25 and also transitioned coverage to Adam Walsh from Annabel Samimy. The stock closed at $1.59 on July 11.Read More
Stifel launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and $38 price target. The stock closed at $23.05 on Feb. 22.Read More
Stifel launched coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and 12-month target price of $23. The stock closed at $11.20 on Friday.
“Our bullish thesis centers on two key pipeline assets: AVP-786 in Phase 3 trials for Alzheimer’s agitation and CTP-543 in Phase 1 studies for alopecia areata,” writes analyst Adam Walsh.Read More